Compelling pre clinical results with compete eradication of all tumours in mice for 7 cancer lines and no reoccurrence
Car T was developed by the University of Pennsylvania. They are generally recognised as the pioneers of Car-T therapy
Only 3 companies are developing therapies targeting CDH17, and we are the ONLY company with Car T in the clinic (soon) and a NK CDH17 in preclinical trial
Gastric, colorectal and NED cancers represent some of the largest oncology segments with single digit to low teen 5 year survival rates - ie huge markets with unmet needs
There are over 5+ million gastric cancer diagnoses annually
CDH17 is a novel antigen that has only recently been attracting attention as a potential cancer target. CD19 and BCMA have been the main antigens targeted by by biotech companies for blood cancers over the last few years.
Paul Hopper was quoted a few years ago as saying that licensing CDH17 Car T from the University of Pennsylvania was one of the best deals he has ever inked in the biotech space.
CDH 17 Car T featured on the cover of Nature Oncology vaccine so it has been rigorously reviewed and independently verified
If the CDH17 Car T works then the NK therapy will also attract a huge valuation
CDH17 Car T is targeting solid tumours and is poised to be the first Car T to demonstrate amazing efficacy like the CD19 Bcell blood cancers
Big pharma will be watching the progress on this trial very closely.
So watch this space!!
(20min delay)